CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Inclusion Criteria: * Documented clinical history of asthma * Forced expiratory volume in 1 second between 60% and 90% of predicted * Using an inhaled corticosteroid (ICS)at a dose equivalent to 200 to 500 mcg daily of beclomethasone (BDP)or equivalent combined with a long-acting beta-2-agonist or an ICS alone at a dose equivalent to \>500 to 1000mcg daily of BDP daily Exclusion Criteria: * Lower respiratory tract infection within 1 month of study entry * Use of systemic corticosteroids within 1 month of study entry * Smoking history of 10 pack years or more Changes in regular asthma therapy within 12 weeks of study entry * Any significant disorder that in the investigator's opinion might put the patient at risk or influence the study outcomes